NNFN Stock Chart & Stats
€3.51
€0.03(0.81%)
At close: 4:00 PM EDT
€3.51
€0.03(0.81%)
Day’s Range― - ―
52-Week Range€1.93 - €5.24
Previous CloseN/A
Volume0.00
Average Volume (3M)360.00
Market Cap
€1.00B
Enterprise Value€1.64K
Total Cash (Recent Filing)€111.13M
Total Debt (Recent Filing)€330.85M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 10, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding321,544,500
10 Day Avg. Volume0
30 Day Avg. Volume360
Financial Highlights & Ratios
PEG Ratio-3.54
Price to Book (P/B)-33.97
Price to Sales (P/S)4.97
P/FCF Ratio126.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.95Price Target Upside98.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€382.74M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginThe sustained revenue ramp indicates meaningful commercial traction across MannKind’s product activities, while consistently high gross margin supports attractive unit economics. If growth continues, this combination can provide operating leverage and improve the company’s ability to fund development internally.
Technosphere Platform And PortfolioMannKind’s Technosphere dry-powder platform creates a reusable foundation across commercial products, pipeline candidates, licensing opportunities, and contract manufacturing. Its portfolio and United Therapeutics partnership provide multiple routes to monetize inhaled-drug expertise beyond a single product.
New Capital And Regulatory MilestoneThe financing adds near-term liquidity and enables MannKind to meet a sizable milestone obligation associated with an FDA-approved product. This supports execution capacity and reduces immediate funding pressure while the company continues commercializing its inhaled-product platform.
Bears Say
Negative Equity And High LeverageNegative equity and materially elevated debt leave MannKind with a thin financial cushion if operating performance weakens. The stressed capital structure can restrict strategic flexibility, increase dependence on capital markets, and make future investment or obligations harder to fund from the balance sheet.
Return To Losses And Cash BurnThe return to substantial losses and negative free cash flow shows that strong revenue and gross margin have not yet translated into durable earnings or cash generation. Continued burn could consume liquidity and require management to prioritize funding needs over expansion or pipeline investment.
Dependence On External FinancingThe recent private placement and preparation for a possible stock offering indicate that external financing remains an important part of MannKind’s funding model. Repeated reliance on equity markets can dilute existing holders and expose operations to financing availability while cash generation remains negative.
MannKind News
NNFN FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was €1.93 and its highest was €5.24 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is €1.00B.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is Nov 10, 2026 which is in 52 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Aug 05, 2026. The company reported -€0.052 earnings per share for the quarter, missing the consensus estimate of -€0.007 by -€0.045.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is -0.05.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 321,544,500 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of -€0.052 in its last earnings report, missing expectations of -€0.007. Following the earnings report the stock price went down -2.206%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Currently, no hedge funds are holding shares in DE:NNFN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.95 (98.13% Upside)
€6.95 (98.13% Upside)
Blogger Sentiment
Neutral
DE:NNFN Sentiment 56%
Sector Average 62%
Sector Average 62%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
77.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mannkind Corp.
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
NNFN Company Deck
NNFN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple near-term commercial and clinical catalysts, solid top-line growth (15% YoY) and strong operational wins (FURO6 prescriber growth, royalties up 9%, SC Pharma synergies exceeding $20M), alongside meaningful progress on pipeline programs (MNKD-201 Phase 1b and Phase 2 start) and an expanded collaboration with United Therapeutics (ralinepag DPI payment and milestone potential). Short-term challenges include seasonality, field reorganization and inventory transitions that pressured Q1 revenue and contributed to GAAP and non-GAAP losses, plus some formulation and development uncertainty for new DPI programs. Management reiterated full-year FURO6 guidance and expects acceleration in H2 tied to the ReadyFlow auto-injector and Afrezza pediatrics launch, indicating confidence that near-term investments will drive longer-term growth.View all DE:NNFN earnings summariesNNFN Stock 12 Month Forecast
Average Price Target
€6.95
▲(98.13% Upside)
Technical Analysis
BioCryst
―
Celldex
―
Sarepta Therapeutics
―
Cogent Biosciences
―
Immunocore Holdings
―